Age-related efficacy of the selective ß3-adrenoceptor agonist mirabegron for the treatment of overactive bladder (OAB): pooled analysis of three prospective, randomised Phase III studies in patients aged >= 65 years

Khullar V1, Cambronero J2, Angulo J3, Nitti V4, Herschorn S5, Van Kerrebroeck P6, Blauwet M B7, Dorrepaal C8, Siddiqui E9, Martin N10

Abstract Category

Detrusor Overactivity

Abstract 331
Non Discussion Poster
Scientific Non Discussion Poster Session 31
1. St Mary’s Hospital, Imperial College, Urogynaecology Department, London, UK, 2. Infanta Leonor Hospital, Department of Urology, Madrid, Spain, 3. Hospital Universitario De Getafe, Department of Urology, Madrid, Spain, 4. NYU Langone Medical Center, Department of Urology, New York, NY, USA, 5. University of Toronto, Division of Urology, Toronto, Canada, 6. Department of Urology, Maastricht University Medical Center, The Netherlands, 7. Astellas Pharma Global Development, Inc., Biostatistics, Deerfield, IL, USA, 8. Astellas Pharma Global Development ,Global Medical Sciences, Leiderdorp, The Netherlands, 9. Astellas Pharma Europe Ltd, Staines, Middlesex, UK, 10. Astellas Scientific and Medical Affairs, Inc, Deerfield, IL, USA